Is ImmuCell Corp. overvalued or undervalued?

As of 14 August 2025, the valuation grade for ImmuCell Corp. has moved from risky to expensive, indicating a shift towards a more negative outlook. The company appears to be overvalued, particularly given its P/B ratio of 2.05 and an EV to EBITDA ratio of 26.30, which suggest that the stock is trading at a premium compared to its earnings potential. Additionally, the negative ROCE of -0.63% and ROE of -0.94% further reinforce concerns about the company's profitability.
In comparison to its peers, ImmuCell Corp. has a significantly higher P/E ratio of 33.88, while ImmunoPrecise Antibodies Ltd. shows a negative P/E of -13.04, indicating that ImmuCell is priced much higher despite its losses. Rani Therapeutics Holdings, Inc. and HOOKIPA Pharma, Inc. also reflect a risky valuation status, highlighting the challenges within this sector. Over the past year, ImmuCell has outperformed the S&P 500 with a return of 57.22% compared to 17.14%, but its longer-term performance shows a decline of -30.47% over three years, suggesting volatility and potential overvaluation concerns.